- Home
- HESM vs LEGN Comparison
HESM vs LEGN Comparison
Compare HESM & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HESM
- LEGN
- Stock Information
- Founded
- HESM 2014
- LEGN 2014
- Country
- HESM United States
- LEGN United States
- Employees
- HESM N/A
- LEGN N/A
- Industry
- HESM Oil & Gas Production
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- HESM Energy
- LEGN Health Care
- Exchange
- HESM Nasdaq
- LEGN Nasdaq
- Market Cap
- HESM 4.9B
- LEGN 5.4B
- IPO Year
- HESM N/A
- LEGN 2020
- Fundamental
- Price
- HESM $38.50
- LEGN $34.00
- Analyst Decision
- HESM Buy
- LEGN Strong Buy
- Analyst Count
- HESM 5
- LEGN 12
- Target Price
- HESM $43.40
- LEGN $77.09
- AVG Volume (30 Days)
- HESM 1.4M
- LEGN 2.0M
- Earning Date
- HESM 07-30-2025
- LEGN 08-08-2025
- Dividend Yield
- HESM 7.18%
- LEGN N/A
- EPS Growth
- HESM 15.91
- LEGN N/A
- EPS
- HESM 2.55
- LEGN N/A
- Revenue
- HESM $1,521,900,000.00
- LEGN $728,303,000.00
- Revenue This Year
- HESM $12.94
- LEGN $65.49
- Revenue Next Year
- HESM $11.19
- LEGN $53.76
- P/E Ratio
- HESM $15.12
- LEGN N/A
- Revenue Growth
- HESM 8.77
- LEGN 112.46
- 52 Week Low
- HESM $33.59
- LEGN $27.34
- 52 Week High
- HESM $44.05
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- HESM 49.71
- LEGN 53.16
- Support Level
- HESM $38.67
- LEGN $33.84
- Resistance Level
- HESM $40.04
- LEGN $35.29
- Average True Range (ATR)
- HESM 0.82
- LEGN 1.96
- MACD
- HESM 0.02
- LEGN 0.24
- Stochastic Oscillator
- HESM 54.42
- LEGN 52.16
About HESM Hess Midstream LP Share
Hess Midstream LP owns, operates, develops, and acquires a diverse set of midstream assets and provides fee-based services to Hess and third-party customers. It conducts its business through three operating segments: gathering, processing and storage, and terminaling and exporting. The company derives the maximum revenue from the gathering segment. Its gathering segment consists of the following assets namely Natural Gas Gathering and Compression; Crude Oil Gathering and Produced Water Gathering and Disposal.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.